AB Science expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027
AB Science SA said it expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027, revising its operating plan after a GCP inspection by France, Denmark and Greece authorities.
AB Science SA said on Sept 29 it has updated its development plan and financial calendar after a sponsor Good Clinical Practice inspection by France, Denmark and Greece authorities. The company said it expects to resume the AB8939 Phase 1 study in Q1 2027 and the masitinib Phase 3 study in Q4 2027. AB Science said it has revised its operating plan following the inspection.